FDA approves Eli Lilly's Onswik, a once-weekly basal insulin for type 2 diabetes

The FDA approved Eli Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes. Lilly says it cuts injections by more than 300 a year versus once-daily basal insulin, with U.S. availability expected in the coming months.

Detected & updated continuously · Source: Nebula